Physician profile
Minesh Rajpal
NPI 1568760502
$402,962.21
in general payments reported to CMS, 2019-2025
38 companies · $100K in 2025
The $100K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $96.00 · 2021: $335 · 2022: $62K · 2023: $97K · 2024: $143K · 2025: $100K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $242K · Consulting Fee: $41K · Travel and Lodging: $31K · Food and Beverage: $14K · Honoraria: $11K · Education: $40.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $242,308.50 |
| Consulting Fee | $41,175.39 |
| Travel and Lodging | $31,439.92 |
| Food and Beverage | $13,884.21 |
| Honoraria | $11,400.00 |
| Education | $40.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $89,558.32 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $68,834.43 | 2021-2025 | |
| Amgen INC. | $48,605.63 | 2019-2025 | Tavneos, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46,288.79 | 2023-2025 | Jardiance |
| Akebia Therapeutics INC | $37,230.40 | 2019-2025 | Vafseo, Auryxia |
| Lilly USA, LLC | $32,093.83 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $29,323.87 | 2021-2024 | Benlysta, Jesduvroq |
| Travere Therapeutics, INC. | $14,361.14 | 2022-2025 | |
| Horizon Therapeutics Plc | $13,706.18 | 2021-2023 | Krystexxa |
| Sobi, INC | $5,541.80 | 2024 | |
| Idorsia Pharmaceuticals US INC | $4,618.29 | 2024 | Tryvio |
| Calliditas Therapeutics US INC. | $4,576.14 | 2022-2025 | Tarpeyo |
| Astrazeneca Uk Limited | $3,617.00 | 2023-2024 | |
| Aurinia Pharma U.S., INC. | $2,855.73 | 2021-2024 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $364.51 | 2019-2025 | Jynarque, Voyxact |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $183.53 | 2021-2023 | Livtencity |
| Opko Pharmaceuticals, LLC | $154.48 | 2019-2024 | Rayaldee |
| Novo Nordisk INC | $152.83 | 2025 | Ozempic, Rybelsus |
| Alexion Pharmaceuticals, INC. | $147.25 | 2019-2023 | Ultomiris |
| Vantive US Healthcare LLC | $128.34 | 2025 | |
| Nxstage Medical, INC. | $119.37 | 2024 | |
| Mallinckrodt Hospital Products INC. | $85.44 | 2020-2022 | |
| Veloxis Pharmaceuticals, INC. | $65.10 | 2023-2025 | Envarsus |
| Daiichi Sankyo INC. | $63.53 | 2022-2023 | Injectafer |
| Novartis Pharmaceuticals Corporation | $63.46 | 2023-2025 | |
| Scpharmaceuticals INC. | $50.11 | 2025 | |
| Vifor Pharma, INC. | $36.98 | 2021-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $32.71 | 2024 | Jynarque |
| Apellis Pharmaceuticals, INC. | $32.31 | 2025 | Empaveli |
| Ardelyx, INC. | $22.57 | 2025 | Ibsrela |
| Genzyme Corporation | $17.09 | 2023 | |
| Ani Pharmaceuticals, INC. | $16.86 | 2025 | Purified Cortrophin Gel |
| Ultragenyx Pharmaceutical INC. | $14.19 | 2023 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minesh Rajpal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.